FMP
Aprea Therapeutics, Inc.
APRE
NASDAQ
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
3.14 USD
0.22 (7.01%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Oren Gilad Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://atrinpharma.comexchange
NASDAQ
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
CIK
0001781983
ISIN
US03836J2015
CUSIP
03836J102
Address
535 Boylston St.
Phone
617-463-9385
Country
US
Employee
7
IPO Date
Oct 3, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
APRE Financial Summary
CIK
0001781983
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
03836J102
ISIN
US03836J2015
Country
US
Price
3.14
Beta
1.74
Volume Avg.
27.47k
Market Cap
17.07M
Shares
-
52-Week
2.15-8.847
DCF
6.78
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.12
P/B
-
Website
https://atrinpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest APRE News
It looks like there's no news available.
